{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:42:46Z","timestamp":1790991766461,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejso.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T12:32:09Z","timestamp":1686141129000},"page":"106950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy"],"prefix":"10.1016","volume":"49","author":[{"given":"Eyal","family":"Mor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Schtrechman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Nizri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Shimonovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nethanel","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Ben-Betzalel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirly","family":"Grynberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Stoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Miodovnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Adileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almog","family":"Ben-Yaacov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Schachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Lahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviram","family":"Nissan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Zippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6629-453X","authenticated-orcid":false,"given":"Shachar","family":"Laks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejso.2023.06.002_bib1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ejso.2023.06.002_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ejso.2023.06.002_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ejso.2023.06.002_bib5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2023.06.002_bib6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2023.06.002_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ejso.2023.06.002_bib8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2023.06.002_bib9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ejso.2023.06.002_bib10","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10236","key":"10.1016\/j.ejso.2023.06.002_bib11","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ejso.2023.06.002_bib12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2023.06.002_bib13","doi-asserted-by":"crossref","first-page":"CT004","DOI":"10.1158\/1538-7445.AM2021-CT004","article-title":"Abstract CT004: adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D\/IV melanoma (CheckMate 915)","volume":"81","author":"Long","year":"2021","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2023.06.002_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2023.06.002_bib15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ejso.2023.06.002_bib16","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10336","key":"10.1016\/j.ejso.2023.06.002_bib17","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejso.2023.06.002_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.ejso.2023.06.002_bib19","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.ejso.2023.06.002_bib20","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ejso.2023.06.002_bib21","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejso.2023.06.002_bib22","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.3390\/cancers13153830","article-title":"Prediction of early response to immune checkpoint inhibition using FDG-PET\/CT in melanoma patients","volume":"13","author":"Kudura","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ejso.2023.06.002_bib23","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","article-title":"FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma","volume":"29","author":"Tan","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2023.06.002_bib24","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s00259-022-05704-0","article-title":"The diagnostic accuracy and clinical impact of FDG-PET\/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma","volume":"49","author":"Andersen","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"7","key":"10.1016\/j.ejso.2023.06.002_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/RLU.0000000000004217","article-title":"18F-FDG PET\/CT during neoadjuvant targeted therapy in prior unresectable stage III melanoma patients: can (early) metabolic imaging predict histopathologic response or recurrence?","volume":"47","author":"van der Hiel","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1016\/j.ejso.2023.06.002_bib26","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1007\/s00330-021-08355-1","article-title":"Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET\/CT in patients with metastatic melanoma treated with BRAF\/MEK inhibitors [published correction appears in Eur Radiol. 2022 Mar 9;:]","volume":"32","author":"Annovazzi","year":"2022","journal-title":"Eur Radiol"},{"issue":"13","key":"10.1016\/j.ejso.2023.06.002_bib27","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.3390\/cancers14133190","article-title":"18FDG PET assessment of therapeutic response in patients with advanced or metastatic melanoma treated with first-line immune checkpoint inhibitors","volume":"14","author":"Rivas","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ejso.2023.06.002_bib28","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/ijc.33926","article-title":"Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma","volume":"150","author":"Ellebaek","year":"2022","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2023.06.002_bib29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ejso.2023.06.002_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","article-title":"Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma","volume":"157","author":"Reijers","year":"2022","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.ejso.2023.06.002_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejso.2023.06.002_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798323005395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798323005395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:52:11Z","timestamp":1760061131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798323005395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0748798323005395"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2023.06.002","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106950"}}